Overview

Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease

Status:
Unknown status
Trial end date:
2019-08-31
Target enrollment:
Participant gender:
Summary
There may be a difference in efficacy of cilostazol and aspirin on progression of white matter changes in cerebral small vessel disease.
Phase:
Phase 4
Details
Lead Sponsor:
Inha University Hospital
Collaborator:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Treatments:
Aspirin
Cilostazol
Glucuronyl glucosamine glycan sulfate